Download the Visual
Lilly is spreading its GLP-1 cash across every major therapy area, mostly through early bets
Eli Lilly’s buyout of AtaiBeckley, a psychedelic medicine developer for treatment-resistant depression, took its year-to-date deal count to 26, and the deals span every major therapy area and modality rather than concentrating on obesity or near-term revenue. Sleuth’s July 2026 map of those 26 deals counts $53 billion in disclosed value, of which only about $13 billion is upfront cash, concentrated in a handful of large buyouts.
The pattern fits Lilly’s position: with no near-term loss of exclusivity (LOE) to replace, it can place many higher-risk, longer-term bets at once.
The 26 deals reach well beyond Lilly’s core franchise
Only two of the 26 deals sit in obesity and metabolic disease, Nimbus Therapeutics and Hanmi. Oncology has five (Ajax, Abbisko, Innovent, Kelonia and CrossBridge Bio), immunology and inflammation four (Ventyx, Orna, Repertoire and CSL), neuroscience and psychiatry four (Centessa, AtaiBeckley, AlzeCure and 4E Therapeutics), infectious disease three vaccine deals (Vaccine Company, Curevo and Limmatech Biologics) and rare and genetic disease two (Ascidian and Sangamo). Six are platform or cross-therapy-area technology deals, including Insilico Medicine and Profluent.
Several are new territory for Lilly: psychedelics through AtaiBeckley, vaccines, in vivo CAR-T through the Kelonia and Orna acquisitions, and AI-driven drug discovery through Insilico and Profluent. Twelve of the 26 are acquisitions and 14 are licensing deals or collaborations. Four involve a China-based partner, including Innovent and Insilico.
The spread is the strategy: most of Lilly’s 2026 deal activity buys options outside obesity, rather than adding to the franchise that funds it.
Upfront cash is concentrated in three buyouts
Three acquisitions carry most of the roughly $13 billion in upfront cash: Centessa at $6.3 billion, Kelonia at $3.2 billion and AtaiBeckley at $2.8 billion, about $12.3 billion together. The only other upfront payments the chart shows are $350 million to Innovent, $115 million to Insilico and $85 million to Repertoire. Six of the 26 deals have no disclosed value.
Most deals are early. Five lead assets are in Phase 2 or later (Hanmi, Ventyx, Centessa, AtaiBeckley and Curevo), and the rest are preclinical, Phase 1 or platform deals.
Outside a few large buyouts, Lilly’s BD runs on milestone-heavy structures that let it place many early bets without large cash commitments.
Tirzepatide’s runway is what makes the breadth affordable
Consensus sales for tirzepatide, orforglipron and the rest of Lilly’s GLP-1 portfolio exceed $70 billion to $80 billion by 2030. Unlike Keytruda (more than $30 billion) and Humira (about $20 billion at its peak), which built revenue over years of indication expansions, most of that potential comes from one indication, obesity, with diabetes, sleep apnea and chronic kidney disease adding to it.
Because that scale arrived early, tirzepatide still has about 11 years of patent life left, the runway Sleuth first described in its January 2025 analysis of Lilly and the LOE cycle.
In Sleuth’s view, if the strategy works, Lilly will have had a decade to soften tirzepatide’s eventual LOE with bets spread across the rest of its portfolio.
Lilly kept dealing after AtaiBeckley
After this analysis, on August 31, 2026, Lilly agreed to acquire Merida Biosciences for up to about $2.9 billion. Merida’s lead asset, MER511, is in Phase 1 for Graves’ disease and is also designed for thyroid eye disease, an area Sleuth maps in its TED and Graves’ disease landscape.
By September 4, 2026, Lilly accounted for 13 of the 29 buyouts announced by the top 15 pharma companies that year, according to Sleuth’s T15 pharma buyout map, which counts acquisitions only.
How Sleuth built this analysis
Which deals count
The map covers 26 disclosed Lilly transactions from January to July 16, 2026: 25 year-to-date deals plus AtaiBeckley, announced July 16. It excludes Lilly’s Cialis divestment.
What the value figures mean
The $53 billion is total disclosed deal value, including milestones, and the roughly $13 billion is disclosed upfront cash, from company press releases and public deal records.
Deal counts and values are as of July 16, 2026. The Merida deal and the T15 buyout count are current as of September 2026. This page is a dated snapshot.
Frequently asked questions about Eli Lilly’s 2026 deals
How many deals has Eli Lilly done in 2026?
Sleuth counted 26 disclosed Lilly transactions from January to July 16, 2026, the 26th being the AtaiBeckley buyout: 12 acquisitions and 14 licensing deals or collaborations. Lilly agreed to acquire Merida Biosciences on August 31, 2026, after that count.
How much has Lilly spent on deals in 2026?
The 26 deals through July 16, 2026 carry $53 billion in disclosed value, but only about $13 billion is upfront cash. Three buyouts, Centessa ($6.3 billion), Kelonia ($3.2 billion) and AtaiBeckley ($2.8 billion), account for about $12.3 billion of it.
Which therapy areas are Lilly’s 2026 deals in?
Every major one. Of the 26 deals through July 16, 2026, oncology has five, immunology and neuroscience four each, infectious disease three, obesity and rare disease two each, and six are platform technology deals.
